Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022
/PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative...
Source: prnewswire.com